U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07356973) titled 'Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma' on Jan. 13.
Brief Summary: Part 1 (dose escalation, safety, and preliminary efficacy) Part 1 is a non-randomised, single-arm design in 12 participants with recurrent GBM suitable for maximal safe surgical resection.
Part 1 will evaluate safety, determine the MTD of irinotecan-ChemoSeed and the RP2D (corresponding to coverage of as much of the resection cavity as possible, up to the MTD) and evaluate efficacy. All Part 1 participants will be administered irinotecan- ChemoSeed concurrent to SoC treatment. Part 1 dose- escalation will start at 72 mg of IRN Part 2, in 135 part...